Halozyme Therapeutics, Inc. (HALO) shareholders
Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 12,612,300 | 10.20% | 13G (passive) amendment | Jun 30, 2025 |
| Vanguard Capital Management | 6,173,547 | 5.21% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HALO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,271,095 | 11.69% | $1.04B | +6,042 | 0.02% |
| Vanguard Capital Management LLC | 5,351,312 | 4.71% | $418.85M | +80,094 | 0.01% |
| Vanguard Portfolio Management LLC | 5,299,008 | 4.67% | $414.75M | +49,802 | 0.02% |
| State Street Corp | 5,179,434 | 4.56% | $405.38M | +241,580 | 0.01% |
| Invesco Ltd. | 3,177,997 | 2.80% | $248.74M | −834,497 | 0.02% |
| Morgan Stanley | 2,832,594 | 2.50% | $221.71M | +270,285 | 0.01% |
| Boston Partners | 2,773,568 | 2.44% | $216.82M | +89,885 | 0.19% |
| Bank Of America Corp /De/ | 2,740,561 | 2.41% | $214.50M | −172,548 | 0.01% |
| Geode Capital Management, LLC | 2,519,951 | 2.22% | $197.28M | +14,165 | 0.01% |
| William Blair Investment Management, LLC | 2,511,050 | 2.21% | $196.54M | −14,925 | 0.59% |
| Snyder Capital Management L P | 2,396,101 | 2.11% | $187.54M | +73,024 | 3.24% |
| Dimensional Fund Advisors LP | 2,089,567 | 1.84% | $163.54M | +9,740 | 0.03% |
| D. E. Shaw & Co., Inc. | 2,006,479 | 1.77% | $157.05M | +137,771 | 0.07% |
| Assenagon Asset Management S.A. | 1,995,286 | 1.76% | $156.17M | +1,973,964 | 0.10% |
| Los Angeles Capital Management LLC | 1,938,035 | 1.71% | $151.69M | +1,248,120 | 0.56% |
| Royal London Asset Management Ltd | 1,810,815 | 1.60% | $141.73M | +200,262 | 0.26% |
| Arrowstreet Capital, Limited Partnership | 1,704,623 | 1.50% | $133.42M | −213,526 | 0.06% |
| Alliancebernstein L.P. | 1,696,538 | 1.49% | $109.65M | −39,963 | 0.04% |
| Two Sigma Investments, LP | 1,653,285 | 1.46% | $129.40M | +68,324 | 0.09% |
| UBS Group AG | 1,492,224 | 1.31% | $116.80M | +578,221 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 668 | 124M | 100.0% | 107 / 270 | 205 / 66 | 16M | 11M |
| Q1 2026 | 636 | 120M | 100.0% | 98 / 234 | 215 / 70 | 24M | 16M |
| Q4 2025 | 618 | 125M | 100.0% | 109 / 216 | 224 / 82 | 20M | 15M |
| Q3 2025 | 603 | 120M | 100.0% | 112 / 187 | 238 / 52 | 17M | 14M |
| Q2 2025 | 551 | 117M | 100.0% | 90 / 181 | 214 / 80 | 17M | 21M |
| Q1 2025 | 549 | 121M | 100.0% | 97 / 216 | 170 / 49 | 12M | 11M |
| Q4 2024 | 508 | 123M | 100.0% | 90 / 180 | 177 / 82 | 13M | 18M |
| Q3 2024 | 509 | 128M | 100.0% | 94 / 179 | 168 / 41 | 31M | 11M |
| Q2 2024 | 460 | 125M | 100.0% | 79 / 161 | 160 / 30 | 8M | 12M |
| Q1 2024 | 413 | 130M | 100.0% | 57 / 163 | 140 / 52 | 12M | 11M |
| Q4 2023 | 410 | 129M | 100.0% | 63 / 146 | 146 / 36 | 15M | 9M |
| Q3 2023 | 389 | 123M | 100.0% | 51 / 136 | 144 / 30 | 9M | 9M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
520 funds held HALO in Q2 2026, 57% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of HALO | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 4,059,222 | 3.58% | $317.72M | 0.26% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,762,787 | 3.32% | $294.51M | 0.01% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,721,119 | 2.40% | $212.98M | 0.11% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,566,912 | 1.38% | $122.64M | 0.26% | Jun 30, 2026 |
| Disciplined Value Mid Cap Fund | 1,430,565 | 1.26% | $111.97M | 0.48% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,412,358 | 1.24% | $110.55M | 1.03% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,359,907 | 1.20% | $106.44M | 0.11% | Jun 30, 2026 |
| Invesco Discovery Fund | 1,254,102 | 1.10% | $83.45M | 1.07% | May 31, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 1,119,086 | 0.99% | $87.59M | 3.11% | Jun 30, 2026 |
| Fullerthaler Behavioral Small-Cap Growth | 968,755 | 0.85% | $75.82M | 1.23% | Jun 30, 2026 |
| Vanguard Explorer Fund | 832,286 | 0.73% | $68.70M | 0.31% | Jul 31, 2026 |
| iShares Biotechnology ETF | 831,875 | 0.73% | $65.11M | 0.72% | Jun 30, 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 709,843 | 0.63% | $55.56M | 0.49% | Jun 30, 2026 |
| iShares Russell Mid-Cap Growth ETF | 693,863 | 0.61% | $54.31M | 0.25% | Jun 30, 2026 |
| Putnam Small Cap Growth Fund | 617,928 | 0.54% | $48.37M | 1.42% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Helen Torley | PRESIDENT AND CEO, Director | 767,780 | 0.68% | Nov 16, 2026 |
| David A. Ramsay | EVP, PRESIDENT, DRUG DELIVERY | 10,000 | 0.01% | Jul 2, 2026 |
| Darren Snellgrove | SVP, Chief Financial Officer | – | – | Jul 2, 2026 |
| Mark Howard Snyder | SVP, CHIEF LEGAL OFFICER | 52,644 | 0.05% | Jun 15, 2026 |
| Cortney Caudill | SVP, CHIEF OPERATING OFFICER | 15,912 | 0.01% | Mar 10, 2026 |
| Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | 42,102 | 0.04% | Feb 24, 2026 |
| Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 173,756 | 0.15% | Feb 27, 2025 |
| Bernadette Connaughton | Director | 42,294 | 0.04% | Oct 8, 2026 |
| Matthew L. Posard | Director | 53,609 | 0.05% | Oct 2, 2026 |
| James M. Daly | Director | 1,169 | 0.00% | Oct 2, 2026 |
| Dannielle Appelhans | Director | 1,161 | 0.00% | Sep 2, 2026 |
| Mahesh Krishnan | Director | 14,462 | 0.01% | Jun 30, 2026 |
| Jeffrey William Henderson | Director | 36,572 | 0.03% | May 7, 2026 |
| Barbara Gayle Duncan | Director | 23,715 | 0.02% | May 7, 2026 |
| James Paul Lang | Director | 4,685 | 0.00% | May 7, 2026 |
| Akiko Moni Miyashita | Director | 24,937 | 0.02% | May 2, 2025 |
| Connie Matsui | Director | 183,035 | 0.16% | Dec 3, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Helen Torley PRESIDENT AND CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −188 | $101.72 | $19.12K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −1,244 | $101.06 | $125.72K | 767,968 |
| Helen Torley PRESIDENT AND CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −4,897 | $100.10 | $490.17K | 769,212 |
| Helen Torley PRESIDENT AND CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −1,586 | $98.89 | $156.84K | 774,109 |
| Helen Torley PRESIDENT AND CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −4,802 | $97.95 | $470.38K | 775,695 |
| Helen Torley PRESIDENT AND CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −7,283 | $96.85 | $705.34K | 780,497 |
| Helen Torley PRESIDENT AND CEO, Director | Nov 16, 2026 | Option exercise | +20,000 | $16.65 | $333.00K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Nov 13, 2026 | Sale(10b5-1 plan) | −12,008 | $100.61 | $1.21M | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Nov 13, 2026 | Sale(10b5-1 plan) | −7,992 | $100.02 | $799.35K | 779,788 |
| Helen Torley PRESIDENT AND CEO, Director | Nov 13, 2026 | Option exercise | +18,448 | $16.65 | $307.16K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Nov 13, 2026 | Option exercise | +1,552 | $18.41 | $28.57K | 769,332 |
| Helen Torley PRESIDENT AND CEO, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −9,289 | $101.49 | $942.78K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −10,711 | $101.09 | $1.08M | 777,069 |
| Helen Torley PRESIDENT AND CEO, Director | Nov 12, 2026 | Option exercise | +20,000 | $18.41 | $368.20K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Oct 8, 2026 | Sale(10b5-1 plan) | −200 | $110.51 | $22.10K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Oct 8, 2026 | Sale(10b5-1 plan) | −11,900 | $110.00 | $1.31M | 767,980 |
| Helen Torley PRESIDENT AND CEO, Director | Oct 8, 2026 | Sale(10b5-1 plan) | −3,090 | $108.91 | $336.53K | 779,880 |
| Helen Torley PRESIDENT AND CEO, Director | Oct 8, 2026 | Sale(10b5-1 plan) | −4,810 | $108.18 | $520.34K | 782,970 |
| Helen Torley PRESIDENT AND CEO, Director | Oct 8, 2026 | Option exercise | +20,000 | $18.41 | $368.20K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Oct 7, 2026 | Sale(10b5-1 plan) | −200 | $113.69 | $22.74K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Oct 7, 2026 | Sale(10b5-1 plan) | −900 | $112.78 | $101.50K | 767,980 |
| Helen Torley PRESIDENT AND CEO, Director | Oct 7, 2026 | Sale(10b5-1 plan) | −10,300 | $111.84 | $1.15M | 768,880 |
| Helen Torley PRESIDENT AND CEO, Director | Oct 7, 2026 | Sale(10b5-1 plan) | −8,600 | $111.03 | $954.87K | 779,180 |
| Helen Torley PRESIDENT AND CEO, Director | Oct 7, 2026 | Option exercise | +20,000 | $18.41 | $368.20K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Oct 6, 2026 | Sale(10b5-1 plan) | −1,780 | $110.81 | $197.25K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Oct 6, 2026 | Sale(10b5-1 plan) | −9,920 | $109.89 | $1.09M | 769,560 |
| Helen Torley PRESIDENT AND CEO, Director | Oct 6, 2026 | Sale(10b5-1 plan) | −6,000 | $109.33 | $656.00K | 779,480 |
| Helen Torley PRESIDENT AND CEO, Director | Oct 6, 2026 | Sale(10b5-1 plan) | −2,300 | $107.90 | $248.17K | 785,480 |
| Helen Torley PRESIDENT AND CEO, Director | Oct 6, 2026 | Option exercise | +20,000 | $18.41 | $368.20K | 787,780 |
| James M. Daly Director | Oct 1, 2026 | Award | +1,169 | – | – | 1,169 |
| Matthew L. Posard Director | Oct 1, 2026 | Sale(10b5-1 plan) | −100 | $110.04 | $11.00K | 53,609 |
| Matthew L. Posard Director | Oct 1, 2026 | Sale(10b5-1 plan) | −1,100 | $109.57 | $120.53K | 53,709 |
| Matthew L. Posard Director | Oct 1, 2026 | Sale(10b5-1 plan) | −3,300 | $108.45 | $357.90K | 54,809 |
| Matthew L. Posard Director | Oct 1, 2026 | Sale(10b5-1 plan) | −730 | $107.17 | $78.23K | 58,109 |
| Matthew L. Posard Director | Sep 16, 2026 | Sale(10b5-1 plan) | −4,000 | $108.99 | $435.96K | 58,839 |
| Matthew L. Posard Director | Sep 16, 2026 | Sale(10b5-1 plan) | −3,100 | $106.13 | $329.00K | 74,735 |
| Matthew L. Posard Director | Sep 16, 2026 | Sale(10b5-1 plan) | −8,896 | $108.04 | $961.12K | 62,839 |
| Matthew L. Posard Director | Sep 16, 2026 | Sale(10b5-1 plan) | −3,000 | $106.83 | $320.49K | 71,735 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 11, 2026 | Option exercise | +20,000 | $18.41 | $368.20K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −15,492 | $107.15 | $1.66M | 772,288 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −4,508 | $107.55 | $484.84K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 10, 2026 | Sale(10b5-1 plan) | −5,412 | $107.58 | $582.22K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 10, 2026 | Sale(10b5-1 plan) | −14,588 | $107.01 | $1.56M | 773,192 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 10, 2026 | Option exercise | +20,000 | $18.41 | $368.20K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −13,304 | $107.22 | $1.43M | 774,476 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 9, 2026 | Option exercise | +20,000 | $18.41 | $368.20K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −6,596 | $107.82 | $711.18K | 767,880 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −100 | $108.67 | $10.87K | 767,780 |
| Dannielle Appelhans Director | Sep 1, 2026 | Award | +1,161 | – | – | 1,161 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 19, 2026 | Sale(10b5-1 plan) | −3,200 | $107.77 | $344.86K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 19, 2026 | Sale(10b5-1 plan) | −9,600 | $107.22 | $1.03M | 770,980 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 19, 2026 | Sale(10b5-1 plan) | −7,200 | $106.36 | $765.79K | 780,580 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 19, 2026 | Option exercise | +20,000 | $18.41 | $368.20K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −9,400 | $104.87 | $985.78K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −4,897 | $104.11 | $509.83K | 777,180 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −5,703 | $103.08 | $587.87K | 782,077 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 18, 2026 | Option exercise | +20,000 | $18.41 | $368.20K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −900 | $98.96 | $89.06K | 786,880 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 17, 2026 | Option exercise | +20,000 | $18.41 | $368.20K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −500 | $100.46 | $50.23K | 786,380 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Halozyme Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 22,676 shares on Aug 25, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Matthew L. Posard Director | Sep 16, 2026 | 34,226 | $3.64M | Sep 16, 2026 | Restricted Stock Units |
| Helen Torley President, CEO, Director | Aug 17, 2026 | 240,000 | $23.68M | Aug 17, 2026 | Stock Option Exercise |
| Cortney Caudill Officer | Aug 11, 2026 | 41,702 | $4.30M | Aug 11, 2026 | Stock Option Exercise |
| Bernadette Connaughton Director | Aug 10, 2026 | 1,626 | $167.67K | Aug 10, 2026 | Restricted Stock Units |
| Mahesh Krishnan Director | Jun 29, 2026 | 7,304 | $547.51K | Jun 29, 2026 | Exercise of Stock Options |
| Nicole LaBrosse Former Officer | May 15, 2026 | 14,700 | $986.59K | May 15, 2026 | Restricted stock vesting under a registered plan |
| Helen Torley President, CEO, Director | May 11, 2026 | 101,923 | $6.54M | May 11, 2026 | Stock Option Exercise |
| Bernadette Connaughton Director | May 1, 2026 | 4,875 | $310.34K | May 1, 2026 | Restricted Stock Units |
| Cortney Caudill Officer | Mar 10, 2026 | 8,857 | $599.09K | Mar 10, 2026 | Restricted stock vesting under a registered plan |
| Cortney Caudill Officer | Mar 9, 2026 | 20,000 | $1.36M | Mar 9, 2026 | Exercise of options under a registered plan |
| Helen Torley President, CEO, Director | Feb 3, 2026 | 150,000 | $11.17M | Feb 3, 2026 | Stock Option Exercise |
| Bernadette Connaughton Director | Jan 5, 2026 | 2,000 | $140.62K | Jan 5, 2026 | Restricted Stock Units |
| Helen Torley President, CEO, Director | Oct 1, 2025 | 136,569 | $10.02M | Oct 1, 2025 | Stock Option Exercise |
| Nicole LaBrosse Officer | Sep 10, 2025 | 22,227 | $1.69M | Sep 10, 2025 | Exercise of Stock Options |
| Bernadette Connaughton Director | Sep 2, 2025 | 8,829 | $645.84K | Sep 2, 2025 | Restricted Stock Units |
Congress trades
7 trades in Halozyme Therapeutics reported by 3 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | Sold (part) | Sep 29, 2026 | $1K–15K | Oct 12, 2026 |
| Gilbert Cisneros CA31 | Bought | Mar 9, 2026 | $1K–15K | Apr 7, 2026 |
| Gilbert Cisneros CA31 | Sold (part) | Mar 24, 2025 | $1K–15K | Apr 7, 2025 |
| Josh Gottheimer NJ05 · joint account | Sold (part) | Sep 9, 2024 | $1K–15K | Oct 3, 2024 |
| Daniel Goldman NY10 | Sold | Jul 12, 2023 | $15K–50K | Aug 13, 2023 |
| Josh Gottheimer NJ05 · joint account | Sold (part) | Dec 6, 2022 | $1K–15K | Jan 13, 2023 |
| Josh Gottheimer NJ05 · joint account | Sold (part) | Aug 5, 2022 | $1K–15K | Sep 16, 2022 |
See a number that looks wrong?